Federico Maisano

Dr. Federico Maisano

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2017 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
SBSimona Bussi
Simona Bussi
ACAlessandra Coppo
Alessandra Coppo
CBCatherine Botteron
Catherine Botteron
VFValérie Fraimbault
Valérie Fraimbault
AFAntonello Fanizzi
Antonello Fanizzi
FMFederico Maisano
Federico Maisano
Purpose: To compare the levels of gadolinium in the blood, cerebrum, cerebellum, liver, femur, kidneys, and skin after multiple exposure of rats to the macrocyclic gadolinium‐based contrast agents (GBCAs) gadoterate, gadobutrol, and gadoteridol.Materials and Methods: Fifty male Wistar Han rats were randomized to three exposure groups (n = 15 per group) and one control group (n = 5). Animals in the exposure groups received a total of 20 GBCA administrations (four administrations per week for 5 consecutive weeks) at a dose of 0.6 mmol/kg bodyweight. After a 28‐day recovery period animals were sacrificed and the blood and tissues harvested for determination of gadolinium (Gd) levels. Gd determination was performed by inductively coupled plasma mass spectrometry (ICP‐MS).Results: After 28 days' recovery no Gd was found in the blood, liver, or skin of any animal in any group. Significantly lower levels of Gd were noted with gadoteridol compared to gadoterate and gadobutrol in the cerebellum (0.150 ± 0.022 vs. 0.292 ± 0.057 and 0.287 ± 0.056 nmol/g, respectively; P < 0.001), cerebrum (0.116 ± 0.036 vs. 0.250 ± 0.032 and 0.263 ± 0.045 nmol/g, respectively; P < 0.001), and kidneys (25 ± 13 vs. 139 ± 88 [P < 0.01] and 204 ± 109 [P < 0.001], respectively). Higher levels of Gd were noted in the femur (7.48 ± 1.37 vs. 5.69 ± 1.75 and 8.60 ± 2.04 nmol/g, respectively) with significantly less Gd determined for gadoterate than for gadobutrol (P < 0.001) and gadoteridol (P < 0.05).Conclusion: Differences exist between macrocyclic agents in terms of their propensity to accumulate in tissues. The observed differences in Gd concentration point to differences in GBCA washout rates in this setting and in this experimental model, with gadoteridol being the GBCA that is most efficiently removed from both cerebral and renal tissues.Level of Evidence: 2Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2018;47:746–752.

9 October 2003 in Nutrition Journal
Verified
Journal Article
Open access
Lorenzo MorelliLorenzo Morelli
Lorenzo Morelli
DZDaniela Zonenschain
Daniela Zonenschain
MLMaria Luisa
Maria Luisa
Enzo GrossiEnzo Grossi
Enzo Grossi
FMFederico Maisano
Federico Maisano
MFMichele Fusillo
Michele Fusillo
Use of synbiotic preparations as dietary supplement is believed to be a valid approach to restore and maintain colonic microflora. However, only few papers have been published on the assessment of these food supplements and none of them have used molecular biology techniques to evaluate the effects of the probiotic components. Twelve healthy volunteers were recruited. Faecal samples were taken before and at various time points during the administration period and at day 3 in the post-treatment period. Stool culture were performed and amplified ribosomal DNA restriction analysis was used to detect L. paracasei, the major bacterial component of the synbiotic products. An increase of at least 1 log of L. paracasei-like bacteria was observed in all subjects. An increase of as much as 3 log was seen in subjects who had a low number of L. paracasei-like lactobacilli at the baseline. The counts of L. paracasei-like lactobacilli were found to persist for at least 3 days after discontinuation of intake in healthy volunteers in 7 subjects. Genetic analysis showed that the maiority of vancomicin insensitive lactobacilli were real L. paracasei, as the strains administered with the tested product. This study has shown that the strains of L paracasei administered with a synbiotic dietary supplement are able to survive through the gastrointestinal tract and to persist for at least a few days. It was also shown the efficacy of a synbiotic preparation to positively affect the microflora of healthy volunteers.

1 April 2006
Verified
Journal Article
Closed access
MBMaria Paola Bartolomeo
Maria Paola Bartolomeo
FMFederico Maisano
Federico Maisano

1 February 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
SBSimona Bussi
Simona Bussi
LPLaure Penard
Laure Penard
RBRoberta Bonafe
Roberta Bonafe
CBCatherine Botteron
Catherine Botteron
RCRoberto Celeste
Roberto Celeste
FMFederico Maisano
Federico Maisano
To determine the impact of single and cumulative doses of MultiHance on toxicity, pharmacokinetics, tissue gadolinium presence, behavior and neurological function in juvenile rats. Juvenile male and female rats received either physiological saline or MultiHance at 0.6, 1.25 or 2.5 mmol/kg bodyweight. Animals received either single or six consecutive MultiHance administrations and were sacrificed the day after the last administration or after a 60-day treatment-free period. Animals were assessed for behavior, cognitive function, grip strength, gait, pupillary reflex, and auditory reflex, as well as for physical development, sexual maturation and histopathology. Gadolinium presence in brain, femur, kidneys, liver and skin was determined using inductively coupled plasma-mass spectrometry (ICP-MS). No effects of MultiHance on behavior, cognitive function or any other parameter were noted, even for the highest administered cumulative dose (15 mmol/kg). Gadolinium presence was variable across tissues and decreased during the 60-day treatment-free period. The highest levels were noted in the femur and the lowest levels in the brain. Gadolinium presence in juvenile rat brain following single or repeated MultiHance administrations was minimal and non-impactful.

7 October 2020 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
NGNicol Guidolin
Nicol Guidolin
FTFabio Travagin
Fabio Travagin
Giovanni Battista GiovenzanaGiovanni Battista Giovenzana
Giovanni Battista Giovenzana
AVAdrienn Vágner
Adrienn Vágner
SLSophia Lotti
Sophia Lotti
ZBZsolt Baranyai
Zsolt Baranyai
Collagen can form electrostatic interactions and hydrogen-bonds with macrocyclic GdIII-complexes which might explain their differentin vivoretention.

11 May 2021 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
SBSimona Bussi
Simona Bussi
ACAlessandra Coppo
Alessandra Coppo
RBRoberta Bonafè
Roberta Bonafè
SRSilvia Rossi
Silvia Rossi
SSSonia Colombo Serra
Sonia Colombo Serra
FTFabio Tedoldi
Fabio Tedoldi
Background: Studies of gadolinium (Gd) clearance from animals in the first weeks after administration of gadolinium‐based contrast agents (GBCAs) have previously looked at solitary timepoints only. However, this does not give information on differences between GBCAs and between organs in terms of Gd elimination kinetics.Purpose: To compare Gd levels in rat cerebellum, cerebrum, skin, and blood at 1, 2, 3, and 5 weeks after repeated administration of macrocyclic GBCAs.Study Type: Prospective.Animal Model: One hundred eighty male Sprague–Dawley rats randomized to three groups (n = 60/group), received intravenous administrations of gadoteridol, gadoterate meglumine, or gadobutrol (0.6 mmol/kg for each) four times/week for 5 consecutive weeks. Rats were sacrificed after washout periods of 1, 2, 3, or 5 weeks.Field Strength/Sequence: Not applicable.Assessment: Cerebellum, cerebrum, skin, and blood were harvested for Gd determination by inductively coupled plasma‐mass spectrometry (15 animals/group/all timepoints).Statistical Tests: Anova and Dunnett's test (data with homogeneous variances and normal distribution). Kruskal–Wallis and Wilcoxon's rank sum tests (data showing nonhomogeneous variances or a non‐normal distribution, significance levels: P < 0.05, P < 0.01, and P < 0.001).Results: Gd levels in cerebellum, cerebrum, and skin were significantly lower after gadoteridol than after gadoterate and gadobutrol at all timepoints. Mean cerebellum Gd concentrations after gadoteridol, gadoterate, and gadobutrol decreased from 0.693, 0.878, and 1.011 nmol Gd/g at 1 week to 0.144, 0.282, and 0.297 nmol Gd/g at 5 weeks after injection. Similar findings were noted for cerebrum and skin. Conversely, significantly higher Gd levels were noted in blood after gadoteridol compared to gadobutrol at 1, 2, and 3 weeks and compared to gadoterate at all timepoints.Data Conclusion: Gadoteridol is eliminated more rapidly from rat cerebellum, cerebrum, and skin compared to gadoterate and gadobutrol in the first 5 weeks after administration, resulting in lower levels of retained Gd in these tissues.Evidence Level: 1Technical Efficacy: Stage 5